Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Robyn, Schecter"'
Autor:
Pierre Duquette, Michael Yeung, Soukaïna Mouallif, Hamid Reza Nakhaipour, Paola Haddad, Robyn Schecter
Publikováno v:
PLoS ONE, Vol 14, Iss 1, p e0210417 (2019)
BackgroundCompliance to disease modifying therapy (DMT) is associated with a reduced risk of relapse, lower healthcare resource utilization, and improved health-related quality of life in patients with multiple sclerosis (MS). Our objective was to as
Externí odkaz:
https://doaj.org/article/aa68feb9f4eb45bab2d200be24020714
Autor:
Hamid Reza Nakhaipour, Umakanth Vudumula, Jean K. Mah, Robyn Schecter, Nicholas Adlard, Guillaume Sébire, V. Khurana, Daniela Pohl
Publikováno v:
Journal of Medical Economics. 23:1525-1533
To evaluate the cost-effectiveness of fingolimod versus interferon (IFN)-β1a at a dose of 30 μg per week for the treatment of relapsing pediatric-onset multiple sclerosis (POMS) in Canada. A discrete-time Markov model was developed to compare fingo
Autor:
Hamid Reza Nakhaipour, Virginia Devonshire, Katayoun Alikhani, Fabrizio Giuliani, Catherine Larochelle, Robyn Schecter, Tania Bruno, Jiwon Oh, Paul S. Giacomini
Publikováno v:
Neurodegenerative Disease Management. 9:301-317
Identifying the transition of relapsing-remitting multiple sclerosis (MS) to the secondary-progressive MS form remains a clinical challenge due to the gradual nature of the transition, superimposed relapses, the heterogeneous course of disease among
Autor:
Brian J. Ward, Francois Grand'Maison, Liesly Lee, Robyn Schecter, Francois Emond, Michael Yeung, Pierre Laneuville, Sarah A. Morrow
Publikováno v:
Current Medical Research and Opinion. 34:1419-1430
Multiple sclerosis (MS) is a chronic disease which usually begins in young adulthood and is a lifelong condition. Individuals with MS experience physical and cognitive disability resulting from inflammation and demyelination in the central nervous sy
Autor:
N. Lara, V. Khurana, Mark S. Freedman, Pierre Duquette, Liesly Lee, G. Vorobeychik, Robyn Schecter, Hamid Reza Nakhaipour, Francois Grand'Maison, P Haddad
Publikováno v:
Current medical research and opinion. 35(5)
There is limited evidence on the effectiveness and healthcare costs of switching to fingolimod versus another first line injectable therapy (FLIT) in patients with relapsing multiple sclerosis (RMS) who have already been treated with FLIT.The objecti
Autor:
Marcelo Kremenchutzky, Y Lapierre, Robyn Schecter, Michael Yeung, Paul O'Connor, Mark S. Freedman, Virginia Devonshire
Publikováno v:
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 43:278-283
Background: The Canadian GILENYA® Go ProgramTM provides education and support to people with relapsing-remitting multiple sclerosis during fingolimod treatment. Methods: Data were collected and analyzed from the time of the first individual enrolled
Publikováno v:
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 43:33-43
Multiple sclerosis is a chronic demyelinating disease characterized by focal and diffuse inflammation of the central nervous system resulting in significant physical and cognitive disabilities. Disease-modifying therapies targeting the dysfunctional
Autor:
Frederica de Takacsy, Robyn Schecter, Serge Gauthier, Sharon Cohen, John S. Sampalis, Alain Robillard, Diane Colizza, Sandra E. Black
Publikováno v:
Current Medical Research and Opinion. 29:989-1000
To assess the real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease (AD) in Canada.Eighteen-month observational, prospective, multi-center, open-label study conducted on A
Autor:
Serge Gauthier, Angela Juby, Robyn Schecter, William B. Dalziel, Explore investigators, Bonita Rehel
Publikováno v:
Current Medical Research and Opinion. 26:1149-1160
Objective To evaluate, in a real-world clinical setting, the efficacy of rivastigmine in the management of six symptoms commonly associated with Alzheimer's disease (AD). Methods This was a naturalistic, prospective, open-label, multi-centre, post-ma
Autor:
Francois Grand'Maison, Sarah A. Morrow, Francois Emond, Brian J. Ward, Liesly Lee, Pierre Laneuville, Robyn Schecter, Michael Yeung
Publikováno v:
Neural Regeneration Research
Multiple sclerosis (MS) is characterized by chronic inflammation in conjunction with neurodegeneration within the central nervous system. Most individuals with MS begin with a relapsing remitting course that later transitions to secondary progressive